Secoisolariciresinol — SDG (Lignan · Phytoestrogenic · Cardiovascular)

Compound	Secoisolariciresinol (SDG)
Chemical class	Polyphenol — Lignan (Plant Lignan Precursor to Enterolignans)
CAS	580-72-3
Primary source	Linum usitatissimum (flaxseed / linseed) — richest dietary source
Key applications	Phytoestrogenic, cardiovascular, cancer risk reduction (observational)
Claim strength	Moderate
Typical form	Flaxseed lignan extract (SDG); ground flaxseed
Buy from Herbuno	Request availability and bulk pricing →

Name origin: Secoisolariciresinol is a secolignan — a “seco” (ring-opened) form of the lariciresinol parent structure. SDG refers to the diglucoside form (secoisolariciresinol diglucoside) — the predominant commercial form from flaxseed, where SDG is esterified to hydroxycinnamic acid moieties and glucosylated. Traditional use: Flaxseed has been cultivated for over 5,000 years for fibre and oil. Traditional use as a laxative, anti-inflammatory, and nutrient-dense food is extensive across ancient Egyptian, Greek, and Ayurvedic traditions. Flaxseed lignan content was not specifically targeted in traditional use; its phytoestrogenic significance was identified through modern research. Research trajectory: SDG has a substantial evidence base as the predominant dietary lignan precursor to enterolignans (enterolactone, enterodiol), which are produced by gut microbiota from SDG and are the primary circulating lignan bioactives in humans. Epidemiological and clinical evidence covers breast cancer risk, cardiovascular biomarkers, and menopausal symptoms. Commercial source: Flaxseed lignan extract (SDG) is commercially available from specialist suppliers; whole flaxseed and flaxseed meal are widely available. Contact Herbuno for SDG lignan extract availability.

---

Evidence for SDG Applications

Phytoestrogenic and menopausal support: SDG and its enterolignan metabolites (enterolactone, enterodiol) are weak ERβ agonists. Multiple human RCTs with flaxseed supplementation show reductions in hot flush frequency and improvements in menopausal quality of life scores, though effect sizes are modest versus soy isoflavone preparations. Claim strength: Moderate.

Cardiovascular lipid modulation: Multiple human RCTs with flaxseed supplementation (whole seed, meal, or SDG extract) demonstrate reductions in total cholesterol, LDL-C, and modest HDL improvements. Meta-analyses support lipid-lowering activity consistent across study designs. Mechanisms include fibre-mediated bile acid sequestration (from whole flaxseed) and ER-mediated lipid gene regulation (from SDG). Claim strength: Moderate.

Breast cancer risk (observational): Cohort studies associate higher urinary enterolactone levels (reflecting SDG/lignan intake) with reduced breast cancer incidence and improved survival after diagnosis. These are observational associations; RCTs testing cancer prevention are not available. Position as epidemiological association only. Claim strength: Moderate (epidemiological; no RCT).

---

Dosage & Formulator Specification

Clinical studies: 25–40 g/day ground flaxseed (delivering ~50–150 mg SDG/day) for cardiovascular and menopausal endpoints. For concentrated SDG lignan extract: 50–300 mg/day SDG. Enterolactone production from SDG is gut microbiome-dependent — similar to the equol producer variability for soy isoflavones, not all individuals convert SDG to enterolignans efficiently.

Flaxseed lignan extract (SDG) is available from specialist botanical suppliers at 20–40% SDG content. Commercial flaxseed products (ground seed, meal, oil) are widely available but note that flaxseed oil contains essentially no lignans — lignans are concentrated in the seed coat and are removed with the oil fraction. Specify ground flaxseed, flaxseed meal, or SDG extract for lignan supplementation; flaxseed oil is not an SDG source. Contact Herbuno for SDG extract availability.

---

Frequently Asked Questions — Secoisolariciresinol

What are enterolignans and how do they relate to SDG?
Enterolignans (enterolactone and enterodiol) are produced by gut bacteria from plant lignans, primarily SDG from flaxseed and lariciresinol/pinoresinol from other plant sources. They are the primary circulating lignan bioactives in humans after flaxseed consumption. Enterolactone in particular is associated with cancer risk reduction in epidemiological studies. Production efficiency varies by individual gut microbiome composition — not all individuals efficiently convert SDG to enterolignans.

Is flaxseed oil a good source of SDG for supplementation?
No. Flaxseed oil contains omega-3 fatty acids (ALA) but essentially no lignans — the lignan content is concentrated in the seed coat (hull) and is mostly discarded during oil pressing. Ground flaxseed, defatted flaxseed meal, or concentrated SDG lignan extract are the appropriate sources for lignan supplementation. This is a common misconception in supplement marketing.

Can SDG be combined with omega-3 fatty acids from flaxseed oil for a combined flaxseed formulation?
Yes — combining SDG lignan extract with flaxseed oil or ALA delivers the two distinct bioactive fractions of flaxseed (lignan phytoestrogenic and cardiovascular effects from SDG; omega-3 anti-inflammatory and cardiovascular effects from ALA). Whole ground flaxseed naturally contains both, but in a format that requires refrigeration and has limited shelf life. A combined SDG extract + flaxseed oil soft gel achieves both bioactive fractions in a stable, concentrated supplement format.

Is SDG from flaxseed safer than soy isoflavones for hormone-sensitive conditions?
SDG and its enterolignan metabolites have substantially lower ER affinity than soy isoflavones — enterolactone ERβ affinity is approximately 100-fold lower than genistein. This suggests a more modest phytoestrogenic burden from flaxseed lignans at typical supplement doses. The same precautionary advisory framework applies for hormone-sensitive conditions, but the theoretical risk from lignans is proportionally lower than from concentrated isoflavone preparations.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery